Emergent BioSolutions has agreed to acquire Ireland-based Adapt Pharma for an upfront payment of $635m, followed by up to $100m in potential sales-based milestones through 2022.

According to the deal, the upfront payment comprises $575m in cash and $60m in Emergent common stock, subject to adjustments.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The deal includes the acquisition of Adapt Pharma’s lead product Narcan Nasal Spray, which is a needle-free formulation of naloxone.

It is used for emergency treatment of known or suspected opioid overdose that manifested due to respiratory and/or central nervous system depression.

“Adding this important life-saving product to our portfolio of preparedness solutions allows us to apply our experience gained from two decades of partnering with the US Government.”

Emergent BioSolutions CEO Daniel Abdun-Nabi said: “Adding this important life-saving product to our portfolio of preparedness solutions allows us to apply our experience gained from two decades of partnering with the US Government to safeguard public health against biological and chemical threats to address the devastating increase in deaths due to opioid overdoses, one of the most serious public health threats facing the nation today.”

In addition to the nasal spray, Emergent will gain a pipeline of new therapy and delivery options for opioid overdose.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The agreement also covers Adapt Pharma’s 50 employees across the US, Canada and Ireland.

Emergent BioSolutions estimates the deal to achieve an incremental revenue contribution between $200m and $220m next year.

The acquisition of Adapt Pharma is subject to customary closing conditions and regulatory approvals and is scheduled to be completed in the fourth quarter of this year.

Emergent BioSolutions also recently signed an agreement to buy speciality vaccines developer PaxVax for $270m.

These deals are part of the company’s growth plan goal to generate $1bn in revenue by 2020.